Continuous Infusion of Vindesine for 21 Days
Author Information
Author(s): E.G.E. de Vries, E.F. Smit, D.E.M.M. Vendrig, J.J.M. Holthuis, N.H. Mulder
Primary Institution: University Hospital Groningen
Hypothesis
Can continuous infusion of vindesine improve therapeutic outcomes without increasing toxicity?
Conclusion
The study concluded that vindesine cannot be safely administered for 21 days at the low dose of 0.2 mg/m²/day due to severe neurotoxicity.
Supporting Evidence
- Neurotoxicity was the major complication leading to drug withdrawal in three patients.
- Patients experienced pain and muscle weakness during treatment.
- After stopping the treatment, muscle strength was regained in all patients.
Takeaway
Doctors tried giving a cancer drug called vindesine continuously for 21 days, but it made some patients very sick, so they decided it wasn't safe.
Methodology
The study involved a 21-day continuous infusion of vindesine using an ambulatory pump, with toxicity evaluated at multiple time points.
Limitations
The study had a small sample size and was limited to patients who met specific eligibility criteria.
Participant Demographics
Patients aged 21-75 years with no prior treatment with vinca alkaloids.
Want to read the original?
Access the complete publication on the publisher's website